The complexity of the events that culndnnte in iotimal proliferation aner arterial injury and similsrilien between this response and baign neOplasia suggesl (hat ponwmional medical therapies will eonlinue to he unsuccessful in preventing wewren stenosis after percutaneous eomnary revawdwilstlon. By preventing wll division after Smooth muscle eelI activation, antimltogwdetherapy may inhibit the final commcm pathway in this complex chain of events and oBsel the apparent loss of local growth wnlrd. Colchicine, which caws metephase arrest of cell division. has b+en shuwn in experimental sludies to deerease the extent of atheramahntr ~laaue formation and reduce the swerhv of arterial low dare colchicine (0.6 mg &vice a day orally) dms not prwen~ r&E"MiS.
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The UP of more polenl anGneoplastic agents is limiled by the potential for 8fe.threatming side eUeels. It Is pasiblr that these adverse eLctr can be averted by using novel drug delivery systems Lo administer aotimltogrnic therapy locally at the site of arterial iNury or by uslog low dose sywrgistie eombinatiom of antiprolilralivepg~nts. This review exmnii;oslhcpotential role01 antimi@enic therapy in the prevention ai r&en& rftw cow nary intwenlions and considers the pasjibility of an overlap of the therapeutic realms cd ialerventionel cardmlogy and medical OlXol0gy.
(J An Co11 Cordial 1991; I 7:1268-318) Despite intensive cbnical and experimental invesGgation over the past decade. the incidence of recurrwt Senosis after balloon dilation of coronary anery stewsis has remained remwkably constant. Allhough several animal studies of antiplatelet, anticoagulant and vasodilator therapies have reported favorable reductions in the severity of the intimal proliferative response lo balloon injury, clinical studies (l-4) have failed 10 identify any single pharmacologic agent that consistently inhibits this response. More recently, attempts have been made to modify the endovascular injury inflicted during percutaneous revascularization procedures. These &Tons have included the use of dcviccs that excise. campress or heat atheromatous tissue and others that use laser energy lo ablate obstructive material (5). Preliminary data from follow-up studies (6-8) suggest lbal these procedures may also he associated with an incidence of restenosis that is comparable with that of conventional balloon angioplasty. Moreover, histologic analyses (9.10) have suggested that the intimal proliferative response after these dissimilar injuries may he pathologically indistinguishable from the response to balloon dilation. These findings suggest a limited role for further modiiicatwn cf the nature of the anerial injury.
;.ar this reason, akhough tnese new devices remain a valuable means of o$imizing the initial pmcedural result (II). the focus of attention for many investigators has returned to the evaluation of pharmacologic preventive measures. The agents currently under experimemal investigation include a variety of antineoplastic drugs. The use of such potent therapies has arisen from the recognition I) of the complexity of the factors that lead lo smooth muscle cell activation, and 2) of parallels between the smooth muscle cell proliferative response of restenosis and the apparently unrestricted growth of neoplastic cells.
Stimuli to Intimal Proliferation
The complexity of the vascular reparative response 10 injury has been well reviewed by several inves@tors (12) (13) (14) . If now appears clear that multiple heterogeneous faclon trigger a common response lo injury (Fig. I) . This response consists of medial smooth muscle cell activation characterized by a change in smwth muscle cell phenotype from contractile lo synthetic form, migration of both phenotypos from Lhe arterial media to the intima, exuberant smooth muscle cell proliferation and subsequent synthesis and secretion of extracellular collaw~~~s matrix (H-17) . In some individuals, this process co&ues, apparently unimpeded by normal control mechanisms, until the neointima encroaches on the arterial lumen and compromises coronary Whereas conventional medical approaches to the prevention of restenosis have attempted to inhibit individual components of this response. newer approaches may include inhibition of the induction and expression of smooth muscle cell growth factor receptors and interference with intracellulx~signal hansduct& Less futuristic. perhaps. is the possibility that antimitogenic therapy may inhibit the final common bathway by pr&eoting &dial s&&h muscle cell division and proliietation. Whether it is also necessary to prevent migration and collagen synthesis by nonproliferating smooth muscle cells is at present unknown.
Intimal Proliferation and Neaplasia
A second argument for the evaluation of antineoplastic therapy in this context is the analogy between intiotal pmliferatian and benign neoplasia. In 1973, a pathologic study (24) of atherosclerotic lesions in black women who were heterozygous for glucosed-phosphate dehydrogenase suggested that individual plaques were composed of cells that were monoclonal in origin. This raised the possibility that the underlying pathogen.% of atherosclerosis is focal neoplasia (24). Subsequent investigations (Zs) have bLen inconsistent in supparting or refuting this concept. An even closer analog to the intimal omliferatlon of restenosis may be the f&&n of k&id scan from abnormal *.vounb healing in zeenetically sosceotible individuals. These benian dermal tumors have reduceh growfh factor requirements% cell colture and respond differently from unaffected skin to exogenous growth factors (261. These differences have been attributed to the automine production of growth factors by dcrmal cells. reduce production of growth-inhibitory pep tides or alterations m growth factor receptor activity or postreceptor signal transduction (26).
It is clear from tritiated thymidioe studies that experimentally induced intimal proliferative lesions and. presumably. the lesions of coronary restenosis after balloon dilation are not of monoclonal origin. The cells of these lesions may. however, have altered growth characteristics and responses to mitogens when compared with cells from primary atherosclerotic lesions. lo a recent study by Dansch et al. (27) . cultured human smooth mu& cells obtained from atherectomy of recurrent femoral attery steooses shinved a sigoiftcantly higher baseline growth rate and a heightened proliferative response to platetetdaived growth factor and agrowth factor mixture isolated from bovine brain when compared with cells derived from advanced primary steooses.
Perhaps one of rhc most intrigr,ing similoriries herween rerrenosis and nroplusin ir the apparen! homology berween plot&r.deriwd growfh factor and mitogens released from vmlignanr ne~plasms. A striking stnc~uml. functional and immunologic homology has been noted. for example. be. tween platelet-derived growth factor and p28-. the transforming protein of the simian sarcoma virus (28). and a similar mitoeen has been purified from human osteosarcoma cells. Human astrocytomas have also been shown to express both platelet-derived growth factor and its receptor genes. suggesting that platelet-derived growth factor may act as a potent protcxmcogeoe in the maintenaoce of gmwh of these twoors 129).
Thr unulvgy bcrween coronary resrrnosh and focal benian smoolh mrrscle cell nioploxia with failure of normal growth ron~rol mechanisms is, therefore, an attractive, if somewhat simplistic concept. Indeed. the term "malignant restenosis" has recently found its way into the lexicon of interventional cardiologists to describe the frustratingly rapid and mtractable recorreoce ofcoroaary artery stenoses after a variety of percutaneous coronary interventions. With these considerations in mind, is there a role for antimitogenic therapy in the prevention of restenosis after balloon aogiaplasty? Two classes of antimitogenic agents (colcbicine and the antineoplastic agents) warrant evaluation.
Cokbkine Merhnnurn ol act&m. Cakhicine is an alkaloid derived from the slant Colchicbtm osrronnob. Its medicmal use was described as early as the Is1 century AD and its principal mechanisms of action were described in 1889 by Pemice (30) and later evaluatedindetail by Taylor (31). It binds with high thereby inhibiting the assembly of these organelles and, to a variable extent. causing disassembly of microtubules that have already been formed. Because normal microtubule function is essential for spindle formation, colchicine therapy results in me&phase arrest of cell division (Fig. 2) . In addition, colchicine inhibits other microtubuledependent functions, including the secretion of polymorphonuclear cell and monocyte chemotactic factors (32.33). the synthesis and secretion of collagen (34) and ~ysosonte degranulation after phagocytosis (30). Furthermore, colchicine therapy has been shown to increae collagenase activity (35) and inhibit platelet aggregation and secretion (36). Its principal therapeutic use has been in the treatment of acute gouty arthritis and as prophylactic maintenance therapy for hyperuricemia.
The anti-inflammatory and antifibrotic activity ofthe drug have prompted its evaluation in several nonrheumatologic conditions. In a recent randomized clinical trial of patients with hepatic cirrhosis (37), colchicinc therapy wns nssociated with a reduction in the severity and extent of periportal inflammation and fibrosis and an increase in long-term survival. Colchicine has also been used us an nntineoplastic agent for malignant conditions, including acute leukemia. Its use for these conditions has been limited, however, by a high incidence of side etfects, including hemorrhagic gastroenteritis and bone marrow depression. None!heless, its broad spectrum of antiprolifcrative, anti-inflammatory and antifibrotic activity suggests a potenrial role for colchicine in the prevention of restenosis after percutaneous coronary revascularization procedures.
Ex&nental studies nf cokhirine and vascular injury. This possibility is supponed by a small number of experimental studies. Colchicine has been shown to inhibit to a variable extent the development of atherosclerotic plaques in several animal models (38-40). Hollander et al. (38), for example. showed a reduction in the severity of visible antic atherosclerosis in rabbits fed an atherogenic diet. The lesions that developed in the treated animals contained less free and ester cholesterol and less collagen and elastin than did the lesions of rabbits fed an athcrogenic diet alone. Similarly, in rabbits with established atherosclerosis (39), colchicine therapy during a subsequent hypocholesterolemic regression diet appeared to reduce the severity of intimal fibrous tissue formation. Only one study (41) reponed the use of colchicine to prevent intimal thickening after balloon arterial injury. In the atherosclerotic rabbit model, Currieret al. (41) showed n moderate reduction in the severity of restenosis 4 weeks after iliac arterial balloon dilation in animals treated with high dose (0.2 mgntg per day) but not low dose (0.02 m&g per day) colchicine (Fig. 3) . It should be noted, however, that the chronic high dose colchicine therapy used in this study would rdmo~t certainly not be tolerated in clinical studies.
Clinical restenusis trials. Low dose colchicine therapy was recently evaluated in a randomized placebo-controll&l clinical trial at the Mid-America Heart Institute (42). The majority of the 197 patients enrolled in the study had multilesion or multivessel disease and approximately SO0 coronary stenoses were dilated. Patient~~were radomly assigned to receive colchicine (0.6 mg twice a day orally) or placebo commencing on the day before the angioplasty procedure and continuing throughout the study period. Drug efficacy was evaluated with use of exercise thallium scint'g. raphy 3 months after the procedure and repeat eorotory angiography at 6 months. Although this low dose therapy was reasonably well tolerated in the majority of patients, adverse effects requiring termination of drug therapy occurred in approximately 7% of the treated patients. In a nreliminarv analvsis of the data from the first 145 natients completing the study, the incidence ofrestenosis at Btuonths was 46% in the colchicine-treated group compared with 47% in the placebo group (p = NS).
Antineoplastic Therapy
Experimenlal studies. The use of more potent antimitogenie agents for the prevention of restenosis has not been well studied, predominantly because of the potential hazards of such toxic therapy and the relatively benign clinical consequences of restenosis. The agents used most frequently to treat malignancies of mesenchymal cell origin include vincristine, actinomycin D, doxorubicin. cyclophos- phamide and methotrexate. A regimen of combined low dose intravenous vincristine (0.075 mdkg) and actinomycin D (0.015 "g/kg) was recently evaluated in a rabbit model of aortic endothelial injury (43). Three days after endothelial denudation. the animals treated with antineoolastic theraov had fewer subintimal smooth muscle cells'(l55% YE& 223% of the contra! number) and less evidence of activation (nuclear euchromatization gnd endoplasmic reticular content) by electron microscopy when compared with the control untreated animals. Whether this thenpy has any impact on the degree of subsequent intimal thickening in this model is unknown because longer-term studies were not reported.
Loeyl drug d&very at site of aneioploscr. A more acceptable approach to the systemic admioistration of potentially Me-threatening drug therapy to patients with nonmalignant conditions may be local drug delivery at the site of balloon angioplasty. We investigated the use of the antimetubolite methotrexate given locally for the prevention of intimal proliferation after bal1oo.1 arterial injury in the porcine carotid artery model (44). Methotrexate is a competitive inhibitor ofdihydrofokue reductase, the enzyme responsible for the synthesis of tetrahydrofolate from dihydrofolate. Inhibition of the enzyme results in a cellular deficiency of tetrahydrofolate, a compound essential for the synthesis of pmines and pyrimidines and thus for the synthesis of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). Cellular proliferation is therefore prevented by inhibition of the S phase of the cell cycle (Fig. 2) . Unlike most antineoplastic agents. the elTects of methotrexate can be rapidly reversed with high dose folinic acid (5.formyl tetrahydrofolate) rescue. For this study, the drug was delivered through a specially designed infusion catheter. The catheter has a 4.3F triple lumen shaft with u distal balloon made of polyethylene tetraphthalate. The balloon has 28 holes. 25 rm in diameter, in longitudinal rows (Fig. 41 . In a previous study (45) evaluating this balloon, Ruoresceinated heparin delivered at 5 atm pressure for I min penetrated the full thicknas of a canine arterial wall and remained detecrable for 48 to 72 h.
After balloon angioplasty bilateral carotid angioplasty was performed by direct cutdown under general anesthesia in IS Yucatan minipigs (46). In IO of these animals. methotrcxate 16.25 mg!mlJ was then infused locally at the site of balloon dilation in one carotid artery. The contralateral side was infused with 0.9% saline solution. The local administration of methotrexate did. in fact. result in transient low therapeutic systemic drug levels ranging from 0.7 to 22 &liter (therapeutic range IO to LOCOJ. Because the contralateral side WIE exposed. if only transiently, to circulating methotrexate. five additional animals underwent ~a. mid angioplasty and bilateral infusion of saline solution as "Irue" control animals. Tritium-labeled methotrexate wan used to determine the dumtion of local drug effect. The intramural drug concentration in the treated carotid anery at the site of balloon injury was I .0@3-fold greater than the serum concentration 2 h after drug administtaion and very high tissue cowxntrations were maintained for t7 days. After the surgical procedure, each animal *as maintained on B normal diet for 4 weeks. at which time it was killed and the carotid arteries were resected for histologic analysis.
Pr&ninaq darn from this study f&J su~.ear that de inrimal proliferative respoustse is nor obo/&~and may not even be attenuated using this dose of methotrexate and this delivery system. :':betber the drug itself is ineffective or the duration of hs activity is inadequate with this approach ih unclear at present and is the subject of ongoing avestigation.
Other app'orba.
The potential role of long-term local drug delivery at the site of arterial dilation is the focus of intense research in several academic centers. Other drug delivery systems that may prove to be valuable include drug-impregnated polymer-coated metallic stents. biodegradable drug-eleing polymer stems (47) and genetically primed endothclial cells to coat metallic stews i48J or be delivered directly as P local endothelial cell covering (49). These systems may allow the safe use of potent antiproliferative therapies. including antimitogenie agents. in high local concentrations without systemic side etTects.
Several other approaches warrant further invesrigotion. It may be possible. for example. to find synergistic drug combinations to inhibit intimal proliferation. Low dose anlimitogenii therapy given orally or parenterrdly for a period of 7 to IO days may be adequate well tolerated therapy if combined with a patent growth factor antagonist. Altemalively. because a substantial propo&n of the wointima is comwsed of collaaenous matrix (some of which may be deri&d from nonp&iferating cells). the combination of an antineoplastic agent with a powerful inhibitor of collagen formation may be valuable.
COllCiUSions
On purely theoretic grwods. antimitogenic therapy ap pears to offer some potental as an lpproach to the prevention of restcnoss. Its use may b-e limited, however, cat only by troublesome systemic side effects. but also by the potentially deleterious effects of inhibition of regrowth of the endothelium. Conceivably. the latter e&ct may actually increase the seventy of restenos~r by prolonging the period of exposure of subintimal tissue. If lhese therapies do prove 10 he successful in reducing the incidence of restenosis. consider&m will need to be given to patient selection criteria for vestment because approximately two thirds of patients undergoing their first percutaneous revascularizalion procedure do not develop recurrent stenosis. One possible mans of identifying individuals at particularly high risk of restenosis may be the examination of material ohtained by coronary atherectomy t9.10.27). In much the same way a biopsy of a neopiastic growth CRD provide information regarding its activity and growth potential, endovascular biopsy using an alherectomy device may give useful information about the probability of subsequent restenosis. Thia possibility is the subject of ongoing research at our institution.
From what is known about the pathologic response to balloon sngioplasty and related interventions. it 6eerns likely that a combined mechxical and pbxmacologic approach will be necessary to optimally treat coronary stenosis and prevent subsequent restenosis. Whether the pharmacologic component of that therapy should be drugs as potentially toxic as the antineaplasric agents is at present unclear. Further evalualion of these agents in experimental models of restenosis seems warranted, however, because this may at the very least provide valuable insights into the patbogenesis of this highly complex process.
